
Blood Management Service

Information for Health Care Professionals



Patient Blood Management Program:

A blood management program utilizes a multidisciplinary team approach and evidence-based practices to assess patients and develop a plan of care that utilizes medical and surgical techniques to reduce blood loss and enhance red blood cell production. The goal is to maintain hemoglobin concentration, optimize hemostasis, and minimize blood loss in hopes of reducing or eliminating the need for a blood transfusion.

Blood Management Service:

We are a group of specialized nurses who collaborate with a transfusion medicine specialist to treat iron deficiency anemia in surgical and obstetrical patients by optimizing iron stores prior to their procedure.



Why is Patient Blood Management Important?

- Reduces care costs for both hospital and patient.
- Improves patient safety.
- Minimizes risk for blood transfusions.
- Improved recovery periods



When to Consult Blood Management Service:

If it has been determined, or suspected, that a patient has iron deficiency anemia, a consult should be sent as soon as surgery is considered. Consults will not delay surgery. The earlier a consult is submitted, results in a greater chance for hemoglobin optimization.

What we Require:

- A completed "Request for Consultation/Referral" Scan for which includes the reasons for the referral. (These can Consultation be found on the Transfusion Manitoba Website).
- Scan for
- Recent (within 6 weeks of consult date) CBC, Ferritin & iron studies (Iron, TIBC).
- Patient height & weight.
- Medical History.
- Allergies.

We require this information to calculate the patient's total iron deficit. If this information is missing, we will not be able to calculate this value, which can result in a delay of treatment.

Candidates for Blood Management Consultation:

Many patients can benefit from patient blood management including those who have:

- Expected high blood loss procedure.
- Pre-operative iron deficiency anemia.
- Low blood volume (low body weight).
- Objections to transfusions.
- Difficult cross match or known antibodies.

Inappropriate Patients for Referral

- Patients receiving dialysis.
- Patients with chronic, non-iron deficiency anemia (Ex. Aplastic Anemia).
- Patients with inflammatory conditions (Ex. Autoimmune).

Patients that should be deferred

• Any patients with an active infection.

Intravenous Iron:

Venofer (Iron Sucrose)

Indicated for treatment of iron deficiency anemia in adults. Patients will typically be prescribed Venofer 300mg IV given every other day up to 900mg. Once the patient completes their infusion(s), they will be followed up with a CBC and reticulocyte count, either seven days or three weeks later, time permitting. The patient's first hemoglobin response to the IV iron is approximately 7 days post infusion, with a full response at 3 weeks, providing that there is not blood loss in this time frame.

Monoferric (Iron Isomaltoside)

Indicated for treatment of iron deficiency anemia in adults.




Patients are typically prescribed 500mg to 1,000mg IV. Full effects of Monoferric can be measured 4 weeks from the initial infusion. CBC, reticulocytes, and ferritin are checked to determine a patient's response. This is not currently available for obstetrical patients.



NDICATIONS FOR GI ENDOSCOPY: Adult males «Post-menopausal females «Unexplained weight loss «Family history of GI cancer «Any associated GI Symptoms such as: Dysphagia, Odynophagia, Dyspepsia, Abdominal pain, Melena, Hematochezia, Tenesmus, Altered bowel habit.

IRON REPLACEMENT: a) Control Blood Loss; b) Warn patients of GI side effects and start slow; c) Ferrous sulfate, gluconate, or fumarate or iron polysaccharide in doses that provide 150-200mg of elemental iron per day (e.g. ferrous sulfate 300mg TID)



Monitoring	 CBC and reticulocytes at 2-4 weeks Goals for iron therapy Reticulocytosis in four days Increasing Hbg > 10 g/L in four weeks Increction of IDA should be observed within 2 - 4 months if appropriate iron dosages are administered and underlying cause of ID is addressed 					Consider blood management consult if your patient has a confirmed iron deficient anemia <i>Higb < 100gH</i> . <i>Ferritin Sag QIL</i> AND •Patient is scheduled for surgery or •Obstetrical patient >13 week gestation with a failed trial of PO iron with a failed trial of PO iron inflammation, renal disease, active inflammation, renal disease, active infections Fax: 204.926.8006				
Recommended Oral Iron Supplements	Maximum adult dose	1 tablet BID	z tablets TID	1 tablet TID	Maximize iron tolerability	•Start at a lower dose 50-80 mg/day build up to 100-200 mg/day	ken after a	 Can switch to EOD dosing if side effects persist 	me to two	
	Formulation (elemental iron)	Tablet 300 mg (100 mg)	Tablet 300 mg (35 mg)	Ferrous Sul- Tablet 300 mg (60 fate mg)			 Best to take on empty stomach GI side effects may be reduced if taken after a meal or at bedtime 		Maximize Iron absorption •Take with vitamin C 250- 500 mg	 Avoid calcium and caffeine within one to two hours of taking iron supplement
	Iron Type	Ferrous Fumarate	Ferrous Gluconate	Ferrous Sul- fate			 Best to take on em Gl side effects may meal or at bedtime 		Maximize Iro •Take with vit	 Avoid calciu hours of takir
Quick guide to Iron deficiency and Iron deficient anemia	Step 3: Iron repletion	Oral iron supplementation •Start low, go slow •Discuss potential GI side effects •Loo to zoo mg of elemental iron per day IV iron Consider if				Oral iron is inappropriate	 Reasonable trial of oral iron has failed Rapid replenish- ment is needed **Avoid RBC trans- fusion unless hemo- dynamic instabil- ity** 			ity**
	Step 2: Investigate cause	Decreased iron availability Decreased absorption – gastric bypass, celiac, IBD, etc • CHF • CHF • CKD • Decreased iron intake				Increased iron need Increased require- ments - Pregnancy and breastfeeding, rapid growth, menstruation (menstrual, Gl, cancer, etc)				
Quick guid Iron	Step 1: Identify iron deficiency	Hemoglobin <120 g/L female Hemoglobin <135 g/ L male	Ferritin < 30 ug/L •gold standard for diagnosing iron	deficient anemia •Acute-phase reac-	reliable in patients	with inflammation or cancer	MCV < 75fL •A decrease repre- sents advanced	deficiency	•MCV may be nor- mal in some patients with IDA	Tsat ⊲20%




Saskatchewan **Health Authority**

Preoperative Anemia Management & Hemoglobin (Hgb) Optimization



At-Risk Patient Populations: Hab <130 a/L (male or female), weight <65 kg, female gender, complex or revision surgery, renal disease, anti-platelet and/or anti-coagulant therapy, hematologic conditions (e.g., thalassemia), 'No Blood'/transfusion-refusal Ideal Timeline for Assessment: Ideally at surgical INTAKE, at time of acceptance for surgery; at least 30 days pre-op



Ex: 20,000-40,000IU SC given on day 21, 14, and day 7 preop, and then day of surgery

-Urgent case: 300 IU/kg pre-op daily x10, day of surgery, then daily x4 post-op CHECK Hgb after every 2 doses to monitor effect

and avoid exceeding safe Hgb targets

√ Patients declining transfusion "No

Patients with pre-existing arterialvenous thrombotic events should be

Blood

monitored closely

surgery date

Blood Management Service

Provincially supporting patients and healthcare professionals to enhance patient care through blood and blood alternative education.

Contact us:

204-926-8006

Visit:

Transfusion Manitoba

Website at

